Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer"
1 Respiratory Department and Early Phase (EPSILYON), Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, UMR Institut National de la Santé et de la Recherche Médicale (INSERM) 1052 Centre National de la Recherche Scientifique (CNRS) 5286, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France.
2 Respiratory Department and Early Phase (EPSILYON), Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, UMR Institut National de la Santé et de la Recherche Médicale (INSERM) 1052 Centre National de la Recherche Scientifique (CNRS) 5286, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France. Electronic address: michael.duruisseaux@chu-lyon.fr.